BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 66, Issue 5 (May 2014)

Acetylcholinesterase Inhibitors for Treatment of Alzheimer's Disease Shunichiro Shinagawa 1 , Masahiro Shigeta 2 1Department of Psychiatry, The Jikei University School of Medicine 2Faculty of Health and Sciences, Tokyo Metropolitan University Keyword: アルツハイマー病 , アセチルコリンエステラーゼ阻害薬 , ドネペジル , ガランタミン , リバスチグミン , Alzheimer's disease , acetylcholinesterase inhibitor , donepezil , galantamine , rivastigmine pp.507-516
Published Date 2014/5/1
  • Abstract
  • Look Inside
  • Reference


Alzheimer's disease (AD) is a neurodegenerative disorder, and is the commonest cause of dementia. Acetylcholinesterase inhibitors (AChEIs) were developed under the cholinergic hypothesis of AD. Therapeutic strategies with these drugs aimed to enhance cholinergic neurotransmission in specific parts of the brain, and to improve the clinical symptoms of AD. Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD. Although these drugs have different pharmacological properties, there is no clear evidence of differences between them with respect to efficacy. It is possible to adapt AChEIs for the pharmacotherapy of other conditions, such as vascular dementia, dementia with Lewy bodies, and Down syndrome.

Copyright © 2014, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
66巻5号 (2014年5月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院